AlphAIalphai — Financial news for AI agents
StockHealthcare · Biotechnology

$GUTS

FRACTYL HEALTH, INC.

Price · $GUTSvia TradingView
AI sentiment · 7d0 articles

No enriched coverage for $GUTS in the last 7 days.

Insider · 30dFeed →

No SEC Form 4 filings for $GUTS in the last 30 days.

Top stories · $GUTSMore →
MAY 13·Stock TitanMed

Fractyl Health (NASDAQ: GUTS) posts Q1 2026 profit but flags going concern risk

Fractyl Health (NASDAQ: GUTS) reported a Q1 2026 net income of $9.2 million, primarily due to a non-cash gain on warrant liabilities, despite an Adjusted EBITDA loss of $18.0 million. The company's cash and cash equivalents of $63.2 million are projected to last into early 2027, but management has expressed substantial doubt about its ability to continue as a going concern for a full 12 months without additional funding. Fractyl also received a Nasdaq notice for failing to meet the minimum bid price requirement.

FEB 25·Stock Titan

GUTS SEC Filings - Fractyl Health 10-K, 10-Q, 8-K Forms

This page provides a comprehensive resource for Fractyl Health (GUTS) SEC filings, including annual 10-K reports, quarterly 10-Q earnings, 8-K material events, and insider trading forms. Recent filings detail board changes, proxy statements for warrant-related votes, and clinical trial updates for their Revita and Rejuva programs. The company also reported widening losses and tightening liquidity, raising substantial doubt about its ability to continue as a going concern, despite positive clinical signals.

DEC 8·Investing.com

Rajagopalan, Fractyl Health CEO, buys $19998 in shares

Fractyl Health, Inc. CEO Rajagopalan Harith purchased 10,416 shares of company common stock for $19,998 on December 4, 2025, increasing his direct holdings to 501,745 shares. This transaction follows a significant net loss reported by Fractyl Health for Q3 2025, though analyst ratings remain positive due to promising clinical trial data for its Revita and Rejuva platforms.

News on $GUTS

All news →